Mehmet Akce, MD
Hematology & Oncology · Birmingham, ALNPI 1639480106
Payments from drug & device makers
Across 389 payments — averaging $13,805 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2.8M
- Merck$1.3M
- Tesaro, Inc.$328K
- Exelixis Inc.$190K
- Genentech, Inc.$176K
- Eisai Inc.$164K
- plus $455K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $2,771,730 |
| Merck | 92 | $1,285,987 |
| Tesaro, Inc. | 14 | $327,774 |
| Exelixis Inc. | 127 | $189,574 |
| Genentech, Inc. | 28 | $175,638 |
| Eisai Inc. | 10 | $164,234 |
| E.r. Squibb & Sons, L.L.C. | 13 | $108,514 |
| Redhill Biopharma Inc. | 18 | $99,748 |
| Incyte Corporation | 6 | $80,594 |
| Boehringer Ingelheim | 3 | $48,566 |
| Pfizer | 8 | $35,044 |
| Astrazeneca UK Limited | 4 | $35,029 |
| GSK | 9 | $27,097 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $5,789 |
| Medivation LLC. | 3 | $4,136 |
| Partner Therapeutics, Inc. | 7 | $4,097 |
| Daiichi Sankyo Inc. | 1 | $1,935 |
| Taiho Oncology, Inc. | 1 | $1,650 |
| Genentech USA, Inc. | 1 | $1,555 |
| Bayer | 10 | $823 |
| Gilead | 1 | $150 |
| Boehringer Ingelheim Espana S.A. | 1 | $127 |
| Novartis | 2 | $117 |
| Ipsen Biopharmaceuticals, Inc | 3 | $97 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $20 |
How this compares
$5,370,047 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Birmingham
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Erica Stringer-ReasorBirmingham$18.1M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
- Mayur NarkhedeBirmingham$4.9M
- Christos VaklavasBirmingham$4.9M
- Lisle NabellBirmingham$3.3M
- Omer JamyBirmingham$2.7M
- Francisco VizcarrondoBirmingham$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.